Three major trials push finerenone beyond its current label
Finerenone, a non-steroidal mineralocorticoid receptor antagonist already approved for chronic kidney disease linked to type 2 diabetes, may be poised for a much broader role. New results presented at the European Renal Association Congress in Glasgow and published across The Lancet, The New England Journal of Medicine and JAMA indicate the drug can slow kidney decline, reduce cardiovascular risk and improve survival-related outcomes in patient groups that fall outside its current recommendation.
The unusual publication spread matters. Seeing related findings appear simultaneously in three of medicine’s most influential journals signals that researchers and editors alike view the data as potentially practice-shaping. The work centers on a simple but important idea: overactivation of the mineralocorticoid receptor is not unique to diabetic kidney disease, so blocking it may benefit a wider range of chronic kidney disease patients.
What the studies found
The largest new signal comes from FIND-CKD, a trial involving 1,584 patients with non-diabetic chronic kidney disease across 24 countries. According to the reported results, finerenone added to standard care significantly slowed kidney function decline. The trial also found a 23% reduction in the combined risk of kidney failure, chronic kidney disease progression, heart failure or cardiovascular death.
A second analysis focused on patients in FIND-CKD with glomerular diseases, a group marked by immune-mediated kidney damage and relatively limited treatment options. In that subgroup, finerenone reduced the risk of kidney failure or chronic kidney disease progression by 26% compared with placebo. It also lowered albuminuria, a key marker of kidney damage, by 42% at 12 months.
A third analysis pooled data from FIND-CKD with two earlier phase III trials. While the supplied source text cuts off before detailing every figure from that pooled study, the overall framing is clear: the total evidence base points to benefits that extend well beyond the narrow population for which the drug is currently approved.
Why this matters
Chronic kidney disease is often progressive, clinically silent in earlier stages and deeply entangled with cardiovascular risk. That makes treatments that can delay worsening kidney function especially valuable. The implication of these studies is not just that finerenone works in more people, but that the mechanism it targets may be relevant across multiple forms of kidney injury.
That could be important for non-diabetic CKD, where patients and clinicians have fewer proven options. It could also matter for glomerular disease, where inflammation, fibrosis and long-term kidney scarring are central features and treatment choices can be limited, complex or poorly tolerated.
The researchers’ framing suggests a possible shift in how kidney disease therapies are categorized. Rather than reserving certain drugs for narrow diagnostic labels, future treatment decisions may increasingly be based on the biological pathways driving damage in each patient.
What comes next
These results do not automatically change prescribing rules overnight. Regulatory authorities will need to review the evidence, and guideline committees will need to weigh the findings against current standards of care. Even so, the momentum is notable. When a drug shows benefits in kidney outcomes, cardiovascular outcomes and broader risk reduction across multiple studies, the pressure to revisit its approved use grows quickly.
The studies also reinforce a wider trend in nephrology: expanding treatment beyond supportive care and into disease modification. That shift has accelerated in recent years, and finerenone’s new data suggest the field may not be done redrawing the boundaries of who can benefit.
For patients, the practical takeaway is straightforward. A medicine once defined mainly by its role in diabetic kidney disease may now have evidence supporting use in a broader chronic kidney disease population. If regulators and guidelines follow the data, millions more patients could eventually be considered for treatment.
Key points
- FIND-CKD tested finerenone in 1,584 patients with non-diabetic chronic kidney disease across 24 countries.
- The trial reported a 23% reduction in a composite of kidney and cardiovascular outcomes.
- A glomerular disease analysis found a 26% lower risk of kidney failure or CKD progression and a 42% reduction in albuminuria at 12 months.
- The findings were presented at the European Renal Association Congress and published across three major journals.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
